Introduction: To report long term results after foldable iris claw phakic intraocular lens (pIOL) implantation for treatment of high myopia. Methods: The medical records of patients who underwent Artiflex (Ophtec BV, Netherlands) or Veriflex (Abbott Medical Optics Inc., USA) pIOL were retrospectively analyzed. Patients with five years of follow-up were included. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), and central endothelial cell density (ECD) were analyzed preoperatively and at 5 years after surgery. The complications observed during and after surgery were also recorded. Results: The study included 23 eyes of 23 patients. Mean preoperative SE was -10.71D±2.84D and improved to -1.60D±0.80D at the postoperative 5-year visit. Mean preoperative and postoperative UDVA were 1.47±0.22 logMAR and 0.26±0.16 logMAR, respectively (p<0.05). Mean preoperative and postoperative CDVA were 0.26±0.15 logMAR and 0.17±0.12 logMAR, respectively (p<0.05). Mean ECD decreased from 2526±268 cells/mm 2 to 2357±295 cells/mm 2 at five years postoperatively. (p<0.05) In two eyes, a temporary, steroid-induced increase in intraocular pressure (IOP) was detected. Discussion and Conclusion: Artiflex/Veriflex pIOL implantation was found safe and effective at 5 years after surgery. However, 5-year follow-up is not sufficient to evaluate its long term endothelial safety profile.
P hakic intraocular lens (IOL) implantation is an option for the surgical treatment of high myopia. [1] Phacik IOL implantation offers some advantages in highly myopic individuals when compared to laser in situ keratomileusis and refractive lens exchange. It may result in a better quality of vision and offer significant vision-related quality-oflife advantages over corneal refractive surgery and has the advantage of correcting greater myopia. [2] Refractive lens exchange, in contrast to phakic, IOL implantation results in loss of accommodation.
There are 2 types of pIOLs: Anterior chamber and posterior chamber. Anterior chamber pIOLs can be further divided into 2 groups: Iris-claw and angle supported. Artiflex (Ophtec BV, Netherlands) or Veriflex (Abbott Medical Optics Inc., USA) phakic IOLs are similar foldable iris claw phakic intraocular lenses. They yield predictable refractive results and they are considered to have good safety. [3] However, there are only a limited number of studies describing longterm clinical outcomes following implantation of these lenses and the results are conflicting. [4] As a result, there is still a need for data on long-term follow-up of these lenses to establish especially their safety profile.
The aim of this study was to report long term efficacy and endothelial safety after foldable iris claw pIOL (Artiflex or Veriflex) implantation for treatment of high myopia.
Materials and Methods
This study followed the tenets of the Declaration of Helsinki, and approval was obtained from the Institutional Review Board. Medical records of patients who underwent Artiflex or Veriflex pIOL implantation were evaluated retrospectively. Only patients with 5-year follow-up were included in the study. Spherical equivalent (SE) of manifest refractive error, UDVA, CDVA, and ECD were evaluated preoperatively and 5 years after surgery. Perioperative and postoperative complications were also recorded.
Preoperative and Postoperative Examinations
All patients underwent a standard detailed anterior and posterior segment examination with a slit lamp. Intraocular pressure was measured with Goldmann applanation tonometer at every visit. An autorefractometer (RM-8800 Autorefractor, Topcon, Tokyo, Japan) was used for keratometry measurements. A LED LCD monitor chart (CC-100 XP, Topcon, Tokyo, Japan) was used for uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA) measurements. Endothelial cell density was measured with a specular microscope (CEM 530, NIDEK, Japan).
Surgical Procedure
Power calculation was performed using the modified vergence formula in the software provided by the manufacturer. Two paracenteses were performed and 0.01% acetylcholine (Miochol-EO, Novartis) was injected into the anterior chamber. A 2.75-mm main incision centered at 12 o'clock was performed with a slit knife. The anterior chamber was filled with a cohesive viscoelastic material (Provisc, Alcon). The IOL was introduced from the main incision and rotated until it was horizontal, and the iris was enclaved in the claws of the pIOL using a special needle introduced from the paracentesis. An iridotomy was performed and the viscoelastic material was removed. The incisions were hydrated with BSS.
Statistical Methods
Statistical analysis was performed using SPSS for Windows (version 21.0; IBM, Armonk, NY). The mean, standard deviation, and frequency were used in the statistical analysis. The assumption of normality was assessed by the ShapiroWilk test. A paired t-test was used to analyze data with a normal distribution, and a non-parametric Wilcoxon signed rank test was used to analyze the data with a non-normal distribution.
Results
The study included 23 eyes of 23 patients. There were 9 (39%) male subjects and 14 (61%) female subjects. The preoperative characteristics are shown in Table 1 . Preoperatively, mean SE was -11.51D±3.47 D and mean CDVA was 0.26±0.15 logMAR. Five years postoperatively, mean SE was 1.60D±0.79D, and mean UDVA improved to 0.26±0.1 logMAR (Table 1) . Five years postoperatively, efficacy index and safety index were 1.07±0.51 and 1.28±0.46, respectively. Preoperative and postoperative cumulative visual acuities are shown in Figure 1 . The mean ECD loss was 6.6% at 5 years postoperatively (Fig. 2) . No patient lost 2 or more lines (Fig. 3 ) and no vision threatening complications occurred during follow up. However, in two patients, elevated intraocular pressures (IOP) were detected at the one month postoperatively. These increases were considered to be steroid-induced as there was no pigment dispersion or pupillary block. In both of these patients, the IOP returned to its baseline levels after cessation of steroid use. 
Discussion
In this study, we evaluated long term results after foldable iris claw phakic intraocular lens (pIOL) implantation for treatment of high myopia. We found that only 4 of 23 (17%) eyes were within ±0.50 D of emmetropia at 5 years. Although refractive predictability after phakic iris-claw has been reported to be high, [1, 2, [6] [7] [8] there is a regression of the refractive effect over time probably due to the progressive nature of pathological myopia. In a study of 399 phakic iris-claw IOLs Güell et al. [5] reported that 10% and 38% of the eyes were within ±0.50 D of emmetropia at 5 years in the 5-mm and 6-mm optic groups, respectively.
Despite the low number of patients within the intended target at five-years, we found the efficacy index was >1 at five-year follow up. In other words, although most of the patients had residual refractive errors, the mean UDVA was better than the mean CDVA. We found that sixty-percent of the eyes gained one or more lines of CDVA and this increase in DCVA is probably the reason for the high efficacy index. Because most of the patients gained at least one line of CDVA safety index was also >1, which means that mean postoperative CDVA was above mean preoperative CDVA. Other studies in the literature also report an increase in CDVA after surgical correction of high myopia. [6, 7] One of the mechanisms of the postoperative increase in CDVA may be the relative magnification of the image and the reduction in visual aberrations after an anterior chamber pIOL implantation when compared to spectacle lenses used in the preoperative determination of CDVA. [8] However, the exact mechanism of increased CDVA is not clear. This increase in the CDVA probably masks the effects of residual refractive error. As a result, despite most of the patients have a residual refractive error, they have an increase in CDVA and a UDVA similar or slightly lower than the preoperative CDVA which results in high efficacy and safety.
Endothelial cell loss is always a source of concern after implantation of a phakic IOL. And there are conflicting results in the literature. Tahzib et al. [9] evaluated 10-year results of a phakic iris-claw IOL and concluded that there was no progressive ECD loss and there was ECD gain at 10-years. Jonker et al. [10] reported that there was a progressive cell loss over ten years follow up and ECD was <1500 cells/ mm 2 in 3.9%, 10 years after implantation. Some authors concluded that ECD loss occurs primarily during the surgical procedure, and the decrease stabilizes after a certain time. [7, 11, 12] It is also possible that endothelial remodeling further complicates the issue and the change in ECD may reflect at least partially a remodeling rather than a loss or gain of ECD. [13] A European prospective multicenter study evaluated the surgical results of Artiflex, and the mean endothelial cell changes were -0.05%, 1.79%, and -1.07% at 6 months, 1 year, and 2 years. [3] In this study we found that endothelial cell loss at five years was 6.6%. The ECD loss in our study is higher than reported by Dick et al. [3] Doors et al. [14] found that a shallow ACD and smaller distance between the pIOL edge and the endothelium were risk factors for ECD loss. Surgical trauma,as well as different pIOL edge and the endothelium distances, may be the reason for the higher endothelial loss in our study. However, because of the retrospective nature of our study, we were unable to measure pIOL edge and the endothelium distance.
The major weaknesses of this study are its retrospective nature, lack of a control group and the absence of pIOL edge and the endothelium distance measurements. These weaknesses make it difficult to draw a conclusion on the endothelial safety profile of the procedure. However, none of the eyes in this study developed endothelial decompensation glaucoma or vision threatening complications during follow-up. Furthermore, number of patients included to our study might be higher.
In conclusion, we found that foldable iris-claw phakic IOL implantation is effective in terms of visual acuity despite residual refractive errors (≥0.50 D) in most of the patients. Also, most of the patients experienced an increase in CDVA. However, ECD loss which is higher when compared to ECD loss of normal non-operated eyes requires further studies with longer follow-up to demonstrate endothelial safety profile.
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